Antibodies to non-structural hepatitis C virus antigens: a link with liver disease activity?
- PMID: 1285245
Antibodies to non-structural hepatitis C virus antigens: a link with liver disease activity?
Abstract
Objectives: The aim of our study was to evaluate the aetiopathogenetic role of hepatitis C virus (HCV) in the genesis of chronic liver disease and hepatocellular carcinoma and the relationship between presence of circulating antibodies against non-structural HCV antigens and disease activity.
Methods: Using a new enzyme-immunoassay capable of detecting, either separately or together, circulating antibodies to structural and non-structural hepatitis C virus antigens, we tested 208 chronic hepatitis B surface antigen (HBsAg) carriers and 144 patients suffering from chronic liver disease.
Results: Among the chronic HBsAg carriers with normal transaminase activity, there were 4% who proved to be anti-HVC positive, compared with 14.5% among those with high serum transaminase. Among subjects with chronic liver disease, 20% of patients with chronic persistent hepatitis, 54% with chronic active hepatitis, 35% with liver cirrhosis and 47% with hepatocellular carcinoma proved to be anti-HCV positive. With regard to the aetiology of liver disease, 13% and 25% of chronic HBV infected patients, with or without anti-delta virus superinfection respectively, had anti-hepatitis C virus antibody. This prevalence was 22% among alcoholic liver disease and 89% among patients with cryptogenic liver diseases. The percentage of subjects with circulating antibodies against non-structural HCV proteins was higher among HBsAg chronic carriers with raised alanine aminotransferase and among patients with chronic active hepatitis and hepatocellular carcinoma.
Conclusions: Many subjects with chronic liver disease have circulating anti-HCV antibodies. Anti-HCV positive subjects, especially those with antibodies to non-structural antigens, are more frequently found among patients with aggressive liver diseases. Among HBsAg chronic carriers the prevalence of anti-HCV was lower in "healthy carriers" and HBeAg positive rather than in HBeAg negative subjects with high alanine aminotransferase. We therefore suggest that there may be a relation between HCV replication, activeness of the liver disease and presence of antibodies to non-structural viral antigens.
Similar articles
-
Prevalence of antibody to hepatitis C virus (anti-HCV) in chronic liver diseases (CLD) in southern Italy.Ital J Gastroenterol. 1990 Feb;22(1):16-8. Ital J Gastroenterol. 1990. PMID: 1966702
-
Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis.Hepatology. 1998 Jul;28(1):231-6. doi: 10.1002/hep.510280130. Hepatology. 1998. PMID: 9657117
-
Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan.Princess Takamatsu Symp. 1995;25:27-32. Princess Takamatsu Symp. 1995. PMID: 8875606 Review.
-
Hepatitis C-related hepatocellular carcinoma. Prevalence and significance.Arch Intern Med. 1993 Jul 26;153(14):1672-7. Arch Intern Med. 1993. PMID: 7687423
-
Cellular and humoral immunity in viral hepatitis.Am J Clin Pathol. 1976 May;65(5 Suppl):866-9. Am J Clin Pathol. 1976. PMID: 85410 Review.
MeSH terms
Substances
LinkOut - more resources
Medical